Recital 3, Regulation (EU) 2021/1686

In forcesince 7 Jul 2021

Article 46(2) of Delegated Regulation (EU) 2016/161 establishes that national competent authorities may inform the Commission of medicinal products which they deem not to be at risk of falsification.